Barclays raised the firm’s price target on C4 Therapeutics (CCCC) to $7 from $5 and keeps an Overweight rating on the shares. The firm says the company’s execution continues.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CCCC:
- C4 Therapeutics: Cemsidomide’s Best-in-Class CELMoD Potential and De‑Risking Clinical Momentum Support Buy Rating
- C4 Therapeutics reports Q4 EPS (18c), consensus (34c)
- C4 Therapeutics price target raised to $30 from $20 at Brookline
- C4 Therapeutics announces first patient dosed in Phase 2 MOMENTUM trial
- CCCC Upcoming Earnings Report: What to Expect?